Oryzon Genomics S.A. (ORY.MC)
EUR 2.66
(1.33%)
EUR 2.66
(1.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.54 Million EUR | 17.14% |
| 2022 | -5.48 Million EUR | 21.69% |
| 2021 | -7.01 Million EUR | -63.26% |
| 2020 | -4.29 Million EUR | 59.29% |
| 2019 | -10.54 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 835.74 Thousand EUR | 127.72% |
| 2024 Q3 | -2.79 Million EUR | -434.31% |
| 2024 Q1 | -3.24 Million USD | -132.12% |
| 2023 Q4 | -1.29 Million EUR | -66.68% |
| 2023 FY | -4.54 Million EUR | 17.14% |
| 2023 Q3 | -779.26 Thousand EUR | 35.17% |
| 2023 Q2 | -1.2 Million EUR | 76.57% |
| 2023 Q1 | -5.13 Million EUR | 0.0% |
| 2022 Q4 | - EUR | 0.0% |
| 2022 FY | -5.48 Million EUR | 21.69% |
| 2021 FY | -7.01 Million EUR | -63.26% |
| 2020 FY | -4.29 Million EUR | 59.29% |
| 2019 FY | -10.54 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Atrys Health, S.A. | -1.58 Million EUR | -187.56% |
| Biotechnologies Assets SA | 2.65 Million EUR | 271.407% |
| Pharma Mar, S.A. | -3.82 Million EUR | -18.871% |
| Laboratorios Farmaceuticos Rovi, S.A. | 220.25 Million EUR | 102.065% |